- Home
- RADX vs NRXP Comparison
RADX vs NRXP Comparison
Compare RADX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- NRXP
- Stock Information
- Founded
- RADX 2021
- NRXP 2015
- Country
- RADX Australia
- NRXP United States
- Employees
- RADX N/A
- NRXP N/A
- Industry
- RADX
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- NRXP Health Care
- Exchange
- RADX NYSE
- NRXP Nasdaq
- Market Cap
- RADX 31.8M
- NRXP 34.7M
- IPO Year
- RADX N/A
- NRXP N/A
- Fundamental
- Price
- RADX $4.30
- NRXP $1.93
- Analyst Decision
- RADX Strong Buy
- NRXP Strong Buy
- Analyst Count
- RADX 1
- NRXP 4
- Target Price
- RADX $15.00
- NRXP $28.25
- AVG Volume (30 Days)
- RADX 40.0K
- NRXP 148.0K
- Earning Date
- RADX 02-26-2025
- NRXP 05-13-2025
- Dividend Yield
- RADX N/A
- NRXP N/A
- EPS Growth
- RADX N/A
- NRXP N/A
- EPS
- RADX N/A
- NRXP N/A
- Revenue
- RADX $204,609.00
- NRXP N/A
- Revenue This Year
- RADX N/A
- NRXP N/A
- Revenue Next Year
- RADX N/A
- NRXP N/A
- P/E Ratio
- RADX N/A
- NRXP N/A
- Revenue Growth
- RADX N/A
- NRXP N/A
- 52 Week Low
- RADX $3.50
- NRXP $1.10
- 52 Week High
- RADX $50.82
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- NRXP 45.32
- Support Level
- RADX N/A
- NRXP $1.63
- Resistance Level
- RADX N/A
- NRXP $2.14
- Average True Range (ATR)
- RADX 0.00
- NRXP 0.17
- MACD
- RADX 0.00
- NRXP 0.03
- Stochastic Oscillator
- RADX 0.00
- NRXP 62.50
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.